Nicole L. Clarke
Research Subjects
Nicole L. Clarke has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Julia I.-Ju Leu
Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
51 shared publications - Maureen E. Murphy
Program in Molecular and Cellular Oncogenesis, The Wistar Institute
51 shared publications - Alexandra Indeglia
University of Pennsylvania 3 Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine Philadelphia, Pennsylvania
50 shared publications - Andrew V. Kossenkov
The Wistar Institute, Philadelphia, Pennsylvania
50 shared publications - Chunlei Shao
Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania
50 shared publications - Cindy Lin
Program in Immunology, Microenvironment and Metastasis, The Wistar Institute, Philadelphia, Pennsylvania
50 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by Archives of Breast Cancer in Archives of Breast Cancer
- Vol. 13 (1) , 118-123
Adenoid Cystic Carcinoma of the Breast: Report of a rare Case and Review of the Literature
Background: Breast cancer is the second most commonly diagnosed cancer and leading cause of cancer-related death among women in the United States. Adenoid Cystic Carcinoma (AdCC) of the breast is a rare subtype, comprising less than 0.1% of cases. Despite its triple-negative profile, it typically carries a favorable prognosis. Case Report: A 55-year-old Hispanic female presented for routine screening mammography. Initial imaging revealed fibroglandular densities and architectural distortion in the right breast (BI-RADS 0). Further evaluation identified an irregular 0.9 × 0.9 × 1.0 cm mass at the 12:30 position and an 18 mm lesion at 12:00, 2.5 cm from the nipple (BI-RADS 4). Lumpectomy and sentinel lymph node biopsy confirmed AdCC (pT2 N0). Radiation therapy was recommended; systemic therapy was not indicated. Conclusion: This case highlights the rare presentation and diagnostic features of breast AdCC, contributing to the limited literature on this uncommon malignancy.
- 23 January 2026
- Published by Archives of Breast Cancer in Archives of Breast Cancer
- Vol. 13 (1) , 118-123
Open AccessAdenoid Cystic Carcinoma of the Breast: Report of a rare Case and Review of the Literature
Background: Breast cancer is the second most commonly diagnosed cancer and leading cause of cancer-related death among women in the United States. Adenoid Cystic Carcinoma (AdCC) of the breast is a rare subtype, comprising less than 0.1% of cases. Despite its triple-negative profile, it typically carries a favorable prognosis. Case Report: A 55-year-old Hispanic female presented for routine screening mammography. Initial imaging revealed fibroglandular densities and architectural distortion in the right breast (BI-RADS 0). Further evaluation identified an irregular 0.9 × 0.9 × 1.0 cm mass at the 12:30 position and an 18 mm lesion at 12:00, 2.5 cm from the nipple (BI-RADS 4). Lumpectomy and sentinel lymph node biopsy confirmed AdCC (pT2 N0). Radiation therapy was recommended; systemic therapy was not indicated. Conclusion: This case highlights the rare presentation and diagnostic features of breast AdCC, contributing to the limited literature on this uncommon malignancy.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Evaluating the association between AA, Y107H variant, and cancer risk.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Evaluating the association between AA, Y107H variant, and cancer risk.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Extra crystallographic data for p53Y107H.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Extra crystallographic data for p53Y107H.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Key Reagents List for this study.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Key Reagents List for this study.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Secondary Validations of top drug hits from HCT116 WT vs Y107H clones.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Secondary Validations of top drug hits from HCT116 WT vs Y107H clones.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S8 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Supplementary Figure S1. The Y107H variant of p53 is comparable to WT p53 for growth suppression and apoptosis. Supplementary Figure S2. The Y107H variant is impaired for transactivation of a subset of p53 target genes, including PADI4, PLTP, and HHAT. Supplementary Figure S3. The Y107H protein is impaired for binding to p53 response elements. Supplementary Figure S4. Structural analysis of the Y107H variant shows similar structure but decreased thermal stability and increased propensity to misfold into mutant p53 conformation. Supplementary Figure S5. Mice with the Y107H variant have increased cancer risk. Supplementary Figure S6. Colorectal cancer cells harboring hypomorphic variants have increased sensitivity to the glutaminase inhibitor CB-839. Supplementary Figure S7. PADI4 is a p53 target and has tumor suppressive activity. Supplementary Figure S8. PADI4 correlates with increased immune signatures and wild-type p53 in human cancers.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S8 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Supplementary Figure S1. The Y107H variant of p53 is comparable to WT p53 for growth suppression and apoptosis. Supplementary Figure S2. The Y107H variant is impaired for transactivation of a subset of p53 target genes, including PADI4, PLTP, and HHAT. Supplementary Figure S3. The Y107H protein is impaired for binding to p53 response elements. Supplementary Figure S4. Structural analysis of the Y107H variant shows similar structure but decreased thermal stability and increased propensity to misfold into mutant p53 conformation. Supplementary Figure S5. Mice with the Y107H variant have increased cancer risk. Supplementary Figure S6. Colorectal cancer cells harboring hypomorphic variants have increased sensitivity to the glutaminase inhibitor CB-839. Supplementary Figure S7. PADI4 is a p53 target and has tumor suppressive activity. Supplementary Figure S8. PADI4 correlates with increased immune signatures and wild-type p53 in human cancers.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Oligos for ChIP-qPCR and qPCR used in this study
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Oligos for ChIP-qPCR and qPCR used in this study
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
RNA-seq of top genes identified in Y107H vs WT LCLs, related to Figure 2.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
RNA-seq of top genes identified in Y107H vs WT LCLs, related to Figure 2.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from An African-specific variant of TP53 reveals PADI4 as a regulator of p53-mediated tumor suppression
RNA-seq of top genes identified in Y107H vs WT LCLs, related to Figure 2.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from An African-specific variant of TP53 reveals PADI4 as a regulator of p53-mediated tumor suppression
RNA-seq of top genes identified in Y107H vs WT LCLs, related to Figure 2.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from An African-specific variant of TP53 reveals PADI4 as a regulator of p53-mediated tumor suppression
Secondary Validations of top drug hits from HCT116 WT vs Y107H clones.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from An African-specific variant of TP53 reveals PADI4 as a regulator of p53-mediated tumor suppression
Secondary Validations of top drug hits from HCT116 WT vs Y107H clones.